DT-216P2
Phase 1/2Recruiting 0 watching 0 views this week๐ค Quiet
36
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Jun 1, 2025 โ Mar 1, 2027
NCT ID
NCT06874010About DT-216P2
DT-216P2 is a phase 1/2 stage product being developed by Design Therapeutics for Friedreich Ataxia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06874010. Target conditions include Friedreich Ataxia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06874010 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Friedreich Ataxia